ArticleJournal of the American College of Cardiology2026
Heart Failure Quality of Care Among Asian Patients in the United States.
Article in Journal of the American College of Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundHeart failure (HF) incidence varies among U.S. Asian populations.
objectivesThe goal of this study was to identify differences in quality of inpatient care among individual groups of Asian patients hospitalized with HF and compared with non-Hispanic White patients.
methodsThis study included 824 U.S. hospitals from the Get With The Guidelines-Heart Failure registry (2015-2023). It evaluated the odds of optimal medical therapy (OMT) (defined as an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker or angiotensin receptor-neprilysin inhibitor for those with an ejection fraction [EF] ≤40%; a beta-blocker for those with an EF ≤40%; and mineralocorticoid receptor antagonist for those with an EF ≤35%) at discharge for HF with reduced EF, and length of stay (LOS) >4 days, defect-free care (OMT, follow-up visit scheduling, HF education) at discharge, and in-hospital mortality among patients with any EF. The study cohorts included Asian Indian, Chinese, Filipino, Japanese, Korean, Vietnamese, and Other Asian vs non-Hispanic White patients.
resultsAmong 7,261 Asian patients with individual Asian group identified (mean age range 69.9-78.8 years; 41%-51% female) vs 768,566 non-Hispanic White patients (mean age 74.6 years; 47% female), the odds of receiving OMT were lower in Vietnamese male patients (adjusted OR [aOR]: 0.68; 95% CI: 0.47-1.00). The odds of longer LOS (>4 days) were lower in Vietnamese male patients (aOR: 0.68; 95% CI: 0.50-0.91) and Filipina female patients (aOR: 0.66; 95% CI: 0.46-0.95). The odds of defect-free care were lower in Filipina female patients (aOR: 0.52; 95% CI: 0.34-0.82). In-hospital mortality did not differ compared with non-Hispanic White patients. Among female Asian patients, there was significant heterogeneity in frequency of LOS >4 days and defect-free care across individual Asian groups.
conclusionsHF quality of care is heterogeneous, with substantial gaps in certain U.S. Asian groups compared with non-Hispanic White patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.